Abiomed's Impella® Technology that Enables Heart Recovery Showcased at TCT 2017 With More Than 30 Presentations

DANVERS, Mass., Oct. 19, 2017 (GLOBE NEWSWIRE) --  Abiomed Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announces that there are more than 30 presentations potentially featuring the Impella^® line of heart pumps scheduled during the 29th Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation, being held October 29 - November 2, at the Colorado Convention Center in Denver, CO.

Impella^® heart pumps are enabling heart recovery for the growing population of undertreated advanced coronary artery disease patients that may benefit from complete revascularization. Abiomed is committed to advancing the science of heart recovery through technology and innovation, education and clinical research. The following initiatives are planned for TCT:

• Abiomed Booth Activities
  Abiomed's booth #1012 will feature clinical data, demonstrations and opportunities for physicians to engage in hands-on simulations of the Impella platform. Abiomed is debuting a new simulation tool that allows physicians to experience the use of hemodynamic support with the left-sided Impella CP^® and the Impella RP^® heart pump, which recently received pre-market approval from the U.S. Food and Drug Administration for support of the right side of the heart. This is a unique training tool for insertion, placement and management of the Impella platform.
   
• ProtectedPCI.com Digital Community
  Abiomed's digital community is the largest source of educational resources on the Impella platform of devices. Materials available include protocols and algorithms for appropriate use, summaries on the latest clinical publications and studies, case recordings and updates from TCT 2017. Learn more and sign up for updates at www.protectedpci.com.
   
• Potential Live Cases Utilizing Impella Devices
  Abiomed anticipates the potential broadcast of several elective live cases utilizing Impella devices from participating sites in the main arena, coronary theater, and structural heart theater in the Colorado Convention Center. Further details regarding these live cases will be announced the day of the scheduled procedures as patient status is subject to change.
   
• Investor Event
  Abiomed will host an investor event on Monday, October 30, from 3:15 — 4:15 p.m. To request attendance, please email [email protected].

The schedule for Protected PCI and cardiogenic shock-related TCT symposia is included below. Additional Impella device-related presentations and poster sessions are anticipated. 

MONDAY, OCTOBER 30

Breakfast Program: TCT Cardiogenic Shock Initiative (TCT-CSI)
Colorado Convention Center, 506-507
7:00 — 8:00 a.m.
Faculty:

William O'Neill, MD; Medical Director, Center for Structural Health Disease, Henry Ford Hospital
Navin Kapur, MD; Director, Acute Circulatory Support Programs, Tufts Medical Center

TUESDAY, OCTOBER 31

Breakfast Program: Management of Complex PCI Patients — Award-Winning Case Presentations
Colorado Convention Center, 502
7:00 — 8:00 a.m.

Evening Program: The Interventional Toolbox for Complex Higher-Risk (and Indicated) Patients (CHIP)
Hyatt Regency Denver, Centennial Ballroom A-C
6:30 — 8:00 p.m.

WEDNESDAY, NOVEMBER 1

Presentation Theater Program: Contrast-Induced Acute Kidney Injury — Preventive Measures That Work
Colorado Convention Center, Presentation Theater 5
11:30 a.m. — 12:30 p.m.

ABOUT IMPELLA HEART PUMPS

The Impella 2.5^®, Impella CP^® and Impella 5.0^® are FDA-approved heart pumps used to treat heart attack patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella 2.5 and Impella CP devices are also approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. Abiomed's right-side heart pump, the Impella RP^® device, is FDA approved to treat patients experiencing acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery. To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit: www.protectedpci.com.

The ABIOMED logo, ABIOMED, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, and Recovering Hearts. Saving Lives. are registered trademarks of ABIOMED, Inc. in the U.S. and in certain foreign countries.

ABOUT ABIOMED 
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit: www.abiomed.com.

**For further information please contact:
Ingrid Goldberg Ward
Director, Investor Relations
978-646-1590
[email protected] 

FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.